A Phase I/II Multi-centre Study of AZD8931 in Combination With Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and in a Selected Population With Low HER2-expressing Locally Recurrent and/or Metastatic Breast Cancer
AZD8931 - THYME
Program
A Phase I/II Multi-centre Study of AZD8931 in Combination With Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and in a Selected Population With Low HER2-expressing Locally Recurrent and/or Metastatic Breast Cancer
Phase I, Phase II
Status
Finished
Tumour subtype:
HER2+
Scenario
Localmente avanzado o metastático
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
José Baselga, MD, PhD (Hospital Universitari Vall d'Hebron, Barcelona)
Sites
